Workshop III: late motor complications of Parkinson's disease.
The aim in the current treatment of Parkinson's disease is to delay L-Dopa administration and to keep the L-Dopa dosage as low as possible. Such a treatment strategy can delay the onset of late motor complications and reduce their severity. L-Dopa remains the most potent anti-parkinsonian medication, but its use for the initial therapy of Parkinson's disease is limited to elderly patients. In all other cases, dopamine agonists, budipine, amantadine and selegiline are primarily used. With the occurrence of late motor complications continuous dopamine receptor stimulation becomes essential. In this situation, combination therapy has to be individualized, with dopamine agonists playing a key role. In addition, COMT inhibitors, budipine, amantadine and selegiline may be used. Anticholinergic drugs are of very limited importance in the current treatment of Parkinson's disease.
Jost
W H
WH
Dept. of Neurology, Deutsche Klinik für Diagnostik, Wiesbaden, Germany.
Berg-Mantkowski
A
A
Baas
H
H
Gemende
I
I
Glass
J
J
Kogan
E
E
Schneider
E
E
Storch
A
A
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000145:classification / Q000503:physiopathology / Q000517:prevention & control*; D004421:Dystonia / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control*; D004493:Education; D006801:Humans; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology
D000978:Antiparkinson Agents